The conservative and often patient-preferred endoscopic approaches are proven procedures but carry a 40% to 70% risk of restenosis. Adjuvant therapies have been investigated to improve restenosis including mitomycin C (MMC), an antibiotic isolated from Streptomyces caespitosus. MMC acts as a chemotherapeutic alkylating agent with antineoplastic and antifibrinogenetic properties. MMC inhibits DNA and RNA synthesis preventing fibroblast proliferation. MMC has been used successfully in ophthalmology, and even in otolaryngology for dacrocystorhinostomy and endoscopic sinus surgery.
LITERATURE REVIEW
Basic science research provides an encouraging theoretical application of MMC to airway stenosis. Cellular effects of MMC include disruption of DNA base pairing, prevention of RNA and protein synthesis, inhibition of fibroblast proliferation, and induction of fibroblast apoptosis.
The effects of MMC have been investigated in multiple animal studies using dog, rabbit, and pig models. The clinical literature has varied results and few randomized controlled trials (RCTs).
One retrospective review compared 1) CO 2 laser and dilation to 2) CO 2 laser and dilatation with steroid injection to 3) CO 2 laser and dilation with topical MMC application. 1 From 1990 to 1995, their treatment protocol consisted of CO 2 laser radial incisions and bronchoscopic dilatation. Between 1995 and 1997, 0.4 mg/mL Depo-Medrol injection was added. After 1997, the steroid was replaced with a topical application of MMC, 0.4 mg/ mL for 4 minutes. The study included 47 procedures on 20 patients, with acquired glottic or subglottic stenosis treated by the senior author over time. Some patients received all three treatment regimens. Treatment failure was defined as persistent airway symptoms, temporary improvement followed by recurrent symptoms, or the need for further procedures. The study demonstrated successful outcomes in 15%, 18.2%, and 75% of its three treatment cohorts, respectively, representing a significant improvement in the MMC cohort.
Another retrospective review of patients with stenosis of the supraglottis, glottis, subglottis, or cervical trachea compared 1) endoscopic treatment consisting only of CO 2 laser radial incisions and rigid dilation to 2) endoscopic treatment plus topical MMC. 2 The study included 67 procedures on 36 patients. Seven patients had endoscopic-only procedures, with six of these patients eventually receiving treatment with MMC. The MMC cohort included 35 subjects. Application of MMC was 5 minutes of either the standard 4% (0.4 mg/mL) solution or, for patients with a preexisting tracheostomy, a supersaturated 10% (10 mg/mL solution). The symptom-free interval was significantly longer for the subjects treated with MMC compared to subjects with CO 2 laser and dilation only (23.2 months vs. 4.9 months). Ultimately, 100% of the endoscopic-treatmentonly group failed requiring additional treatment. In the MMC group, 83.8% of subjects required only one treatment, with no clinically significant recurrent stenosis at postoperative follow-up (mean, 38.4 months; range, 13-60 months). There was a difference in the success from a single treatment between the 4% solution and the 10% solution cohorts (90% vs. 57%, respectively) that the authors attributed to a selection bias, with the more severe stenosis patients receiving the supersaturated solution.
The duration of MMC effect in cell culture and animal model fibroblasts is transient, lasting 3 weeks to <3 months. This duration effect spurred a randomized, prospective, double-blind, placebo-controlled clinical trial in 26 patients with laryngotracheal stenosis. 3 The trial compared a cohort receiving a single application of MMC at the time of radial incision and dilation to a cohort who received an additional second application of MMC 3 to 4 weeks after the initial procedure. The etiologies included stenosis from idiopathic, Wegener's granulomatosis, and postintubation causes. Patients underwent an initial radial CO 2 laser incision, dilation, and 0.5 mg/mL topical MMC application. One month later, all patients underwent a repeat radial CO 2 laser incision and dilation, but they were randomized to receive either a second application of MMC or saline placebo. Finally, patients then underwent a third and final radial CO 2 laser incision and dilation with no MMC or saline application. Patient follow-up ranged from 3 to 5 years. The results demonstrated a significant improvement in the relapse rate at 1 and 3 years from 7% and 36% with a single application of MMC versus 33% and 58% with the second application. Unfortunately, this relapse rate converged at 5 years to 69% and 70% between the two cohorts, respectively. The median interval to relapse was improved from 2.4 years to 3.8 years with the use of a second application, and the authors concluded that MMC delays but does not prevent the recurrence of symptoms in most patients. A pediatric RCT examined the effect of MMC on patients aged 2 to 17 years old following laryngotracheal reconstruction. 4 Patients were randomized to either an application of 0.2 mg/mL MMC or sodium chloride at the time of stent removal or extubation, not at the time of initial surgery. Patients underwent scheduled bronchoscopies for airway evaluation, and the amount of granulation tissue was scored by three blinded reviewers. At the 1-year review, the Data Safety and Monitoring Committee advised the trial be stopped because the Fisher twotailed exact test was calculated as 1.00, demonstrating no benefit. No other results data were provided.
Risks of MMC use have been well documented in the ophthalmology literature. In laryngology, a literature review of the use of MMC in the upper aerodigestive tract found 32 articles encompassing 538 subjects, with side effects in 19 cases (3.53%). 5 The most significant side effect was the deposition of fibrin leading to airway obstruction in four subjects. There were no systemic side effects reported, and importantly, there were no side effects reported in studies that used a postapplication saline rinse. There have been no prospective studies directly comparing application time durations or concentrations of MMC used. However, this review found that MMC use ranged from concentrations of 0.1 mg/mL to 10 mg/mL, application times of 2 to 5 minutes, and frequencies of up to four times.
BEST PRACTICE
Basic science studies support the logic and application of MMC for the inhibition of collagen deposition and enhanced proliferation of epithelial cells. Clinical studies suggest that adjunctive MMC application may delay but not prevent recurrence of airway stenosis. The risk of airway obstruction from exudate is real and should be discussed with the patient as well as its off-label use. The timing, dosage, and application duration remain illdefined. There is a real need for more randomized controlled trials to help determine the usefulness of mitomycin C as an adjuvant therapy in endoscopic treatment of laryngotracheal stenosis.
LEVEL OF EVIDENCE
This review cites two level 1b studies, one level 3b study, and two level 4 studies. There are additional prospective and retrospective articles in the literature not included in this article; however, the authors chose the cited works as representative pieces of the current body of knowledge.
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